Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort.

These changes involved: (1) the number of AD compounds used prior to baseline shortly failed to remain significantly associated with change in waist circumference (β (95%CI) = −0.25 (−0.53, 0.02), p = 0.073, Table S3 ); (2) TCA use during the follow-up became marginally associated with an increase in BMI during the follow-up (β (95%CI) = 0.43 (0.00, 0.87), p = 0.049, Table S4 ); (3) SSRI use prior to baseline shortly failed to reach significance for change in waist circumference (β (95%CI) = −0.85 (−1.73, 0.04), p = 0.061, Table S4 ); (4) Mirtazapine use during the second period of the follow-up became significantly associated with change in BMI (β (95%CI) = −0.72 (−1.37, −0.07), p = 0.030, Table S6 ); (5) Mirtazapine use during the first

also in 4,113 other papers